Objective: Patients with metastatic breast cancer usually accept several lines of chemotherapy. This retrospective study is to analyze the therapeutic effect and tolerance of weekly paclitaxel/gemcitabine combination on patients with metastatic breast cancer. Methods: Paclitaxel 80 mg/m 2 and gemcitabine 800 mg/m 2 were administered sequentially on days 1, 8 and 15 every 28 days. Patients with measurable metastatic breast cancer or locally advanced breast cancer were included. Results: From March 2005 to December 2006, 50 patients received this treatment at Chang Gung Memorial Hospital, Kaohsiung Medical Center. Thirteen (26%) patients accepted this regimen as their first-line treatment for metastatic breast cancer and 25 (50%) patients accepted this regimen after at least three lines of therapies for metastatic breast cancer. The overall response rate was 56% (95% confidence interval: 42.2 -69.8%), 2 patients achieved complete response and 26 patients (52, 95% confidence interval: 38.2 -65.9%) achieved partial response. The median progression free survival was 7.4 months (95% confidence interval: 5.5 -9.3 months), and the median overall survival was 19.0 months (95% confidence interval: 9.7 -28.3 months). Except alopecia, the most common Grade 3/4 toxicities were anemia and leucopenia; the incidences of both were fewer than 10%. Conclusions: The combination of weekly gemcitabine and paclitaxel in patients with advanced breast cancer showed acceptable outcome and excellent toxic profiles. This therapeutic benefit could be achieved in any linage of patients with good performance status; earlier usage of this regimen can provide better result.
INTRODUCTION
The incidence of breast cancer is increasing in Taiwan. Annual new cases in 100 000 people increased from 34.3 in 1994 to 53.1 in 2007. The median age at diagnosis was 51 years, and Stage IV disease accounted for 1 -5% of new cases (http://www.bhp.doh.gov.tw/BHPnet/Portal/ StatisticsShow.aspx?No=201002050001). For early-stage breast cancers, however, the recurrence rate is still up to 20 -30%. Anthracyclines are among the most active drugs as an adjuvant therapy for breast cancers, but side effects such as nausea, vomiting, bone marrow suppression, leukemia and irreversible cardiomyopathy limit their re-administration on relapsed patients. After the first introduction of paclitaxel, more and more cytotoxic agents for breast cancers appear, including docetaxel, platinum analogs, gemcitabine, vinorelbine, capecitabine and now, new epothilones. They can be used alone or in combination and have improved the overall survival in advanced breast cancer patients.
Among these new agents, taxanes have become the standard treatment either for the adjuvant setting or for metastatic breast cancer (MBC). As a single agent for MBC, taxanes generated response rates (RRs) ranging from 6 to 48% (1), the RR is better when taxanes are used as the firstline treatment in metastatic disease (2) . Weekly paclitaxel and triweekly docetaxel are now the most commonly used protocols, both are as effective as each other, but have different toxicity profiles. Several Phase II studies evaluated weekly paclitaxel in patients with MBC (3). This regimen was generally well tolerated with main toxicities being neutropenia and peripheral neuropathy. There was no difference in acute toxicity between old age and young age groups, so for elderly patients with MBC, weekly paclitaxel is also a safe and convenient regimen (4) .
Gemcitabine is another new agent. In previously treated MBC patients, it produced RRs ranging from 12 to 29% with satisfied toxicities at a standard administration of 1200 mg/m 2 on days 1, 8 and 15 every 4 weeks (5,6), whereas in the first-line schedules, the RRs were 14 -37% (7). Median progression-free survival (PFS) with gemcitabine monotherapy was in the range of 2 -6 months, and Grade 3/4 hematologic toxicity has been observed in around 30% of the patients (5,8 -10) .
It is reasonable to combine taxanes and gemcitabine because of different mechanisms and the lack of overlapping toxicities. Paclitaxel and gemcitabine showed sequencedependent synergism (11, 12) . In in vitro study, paclitaxel administered immediately before gemcitabine significantly increased gemcitabine triphosphate (dFdCTP), the active metabolite of gemcitabine accumulation, which might enhance the antitumor activity of gemcitabine (13) . A randomized, Phase III multicenter study was conducted to compare the therapeutic efficacy and safety of gemcitabine (1250 mg/m 2 on days 1 and 8)/paclitaxel (175 mg/m 2 day 1) with that of triweekly paclitaxel (175 mg/m 2 ) alone as the first-line therapy in MBC patients who had been treated with anthracyclines in the adjuvant setting. Significant increase in RRs, time to progression (TTP), and in particular, overall RR (ORR) was noted when gemcitabine was added to paclitaxel. Objective RRs were 26.2% for the paclitaxel arm and 41.4% for the combination arm (P ¼ 0.0002). TTP was 3.98 months for the paclitaxel arm and 6.14 months for the combination arm (P ¼ 0.0002). Median survival was 15.8 and 18.6 months for the paclitaxel and combination arms, respectively (P ¼ 0.0489). Both treatments were well tolerated. However, a higher incidence of Grade 3/4 neutropenia (48 vs. 11%) and febrile neutropenia (5 vs. 1.2%) was reported in patients in the combination arm, also a greater frequency of non-hematologic toxicity such as asthenia (7 vs . 2%), alteration of hepatic function (7 vs. 2%) and peripheral neuropathy (6 vs. 4%) (14 as a 1 h infusion on days 1 and 8. Cycles were repeated every 3 weeks. In this study, they also confirmed the high activity of gemcitabine -taxane combinations in MBC. Split-dose paclitaxel had similar activity and toxicity to the triweekly administration. The RR and TTP of the split-dose paclitaxel arm were 52.2% and 7.0 months (15) . In this trial, Grade 3/4 leukopenia still happened in 57% patients. Despite the availability of new active drugs, MBC remains an incurable disease. Goals of systemic therapy in the advanced and metastatic settings are to maximize the control of symptoms, prevent serious complications and prolong survival while maintaining the quality of life (16) . To achieve these goals, the adverse effects of palliative chemotherapy should be predictable, manageable and reversible.
Currently, most of the reported clinical trials combine triweekly or biweekly taxanes together with either weekly or biweekly gemcitabine. Although the reported RR ranged from 32.2 to 52.2% (17) , there were still substantial amount of Grade 3/4 toxicities, especially on bone marrow function. In order to get a better dose-dense effect but with fewer side effects, we decreased doses of gemcitabine and paclitaxel but were with more frequent schedules. From 2005, we conducted this therapeutic regimen with weekly dosing of paclitaxel and gemcitabine for MBC patients. Safety profile was our major concern, and the RR of tumors and survival status were also recorded.
PATIENTS AND METHODS

ELIGIBILITY CRITERIA
This study was a retrospective analysis of a clinical database of the patients treated with weekly paclitaxel/gemcitabine (wPG). From March 2005, patients with histologically confirmed Stage IIIB -IV breast cancer were eligible for this treatment. Patients should have the Eastern Cooperative Oncology Group (ECOG) performance status 2; adequate organ and bone marrow function defined as hemoglobulin !10 gm/dl, absolute neutrophil count (ANC) ! 1000/mL, platelets !100 000/mL, total bilirubin 1.5Â the upper limit of normal (ULN), aspartate aminotransferase and/or alanine aminotransferase 2.5Â ULN and creatinine 1.5Â ULN. Patients could be chemonaïve, or they had to be diagnosed with progressed or recurrent diseases during previous treatments. Prior treatments, including anthracycline, fluorouracil, a taxane, hormone therapy or target therapy for either adjuvant therapy or for palliative treatments, were allowed. There was no limitation of line-up of their previous systemic anticancer treatments.
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TREATMENT DESIGN
Paclitaxel 80 mg/m 2 was administered intravenously (iv) before gemcitabine on days 1, 8 and 15 over a period of 3 h. Gemcitabine 800 mg/m 2 was given iv on days 1, 8 and 15 over a period of 30 -60 min (ideally 30 min), followed by a 1-week rest period. Each 28-day period was defined as a cycle of therapy. Treatment was stopped in the case of intolerable toxicity or disease progression. A total of six cycles could be administered in patients exhibiting a complete response (CR) or partial response (PR), followed by an alternative treatment; additional cycles were allowed if patients had stable disease (SD) after the total six cycles and patients agreed to go on this wPG regimen. All patients were premedicated with dexamethasone, cimetidine and diphenhydramine.
TOXICITY AND RESPONSE EVALUATION
Toxicity was graded according to the World Health Organization (WHO) Common Toxicity criteria. Dose adjustments during treatment were administered based on ANC and platelet counts examined within 24 h prior to the start of each cycle and clinical assessment of nonhematologic toxicities. For an ANC ,1000/mL and/or a platelet count ,7500/mL or a WHO non-hematologic toxicity Grade 3 (except nausea/vomiting and alopecia) or Grade 4, treatment was delayed until these indicators showed an improvement and the symptoms were relieved. Tumor response was assessed using Response Evaluation Criteria in Solid tumors (RECIST) (18) , with computed tomography scans at base. Bone scan and chest X-ray were used as adjuvant evaluation tools.
STATISTICAL ANALYSIS
The outcome measurement of this treatment included OS, defined as the time from treatment with wPG to death from any cause, censored at the last date known alive. PFS was defined as the time from treatment with wPG to the first documented progression and RR defined as the sum of PR and CR rates. The x 2 test and Fisher's exact test were used to test the correlation between treatment outcomes and clinical features such as age, treatment history and histologic features of tumors. A P value ,0.05 was considered statistically significant. The median survival and PFS time were estimated with the Kaplan -Meier method, whereas the log-rank test was used to compare the time to event distributions.
RESULTS
PATIENT CHARACTERISTICS
From March 2005 to December 2006, 50 patients with advanced breast cancer accepted wPG. All patients were available for toxicity and efficiency analysis. A summary of patient characteristics is shown in Table 1 . The median age at treatment was 53 years (range 27 -76 years). Most patients had ECOG performance status 1 (68%). Only one patient (2%) had a locally advanced breast cancer (LABC), and others had distant metastases. The median number of metastatic organ site of disease was 2 (range 1 -4); most of them were visceral metastases (68%). Estrogen receptors (ER) and progesterone receptors were defined as positive if more than 1% cancer cells were considered positively stained; Her-2/neu positive was defined as either strong and Fig. 1 ), and the median OS was 19.0 months (95% CI: 9.7-28.3 months; Fig. 2 ).
Responses differed between different linage. wPG line-ups as the first-or second-line treatment for MBC showed a significant better response than that in a later line-up (P ¼ 0.012). Previous taxane or anthracycline exposure did not influence therapeutic response to wPG, but there was a trend that fluorouracil-pretreated patients responded worse to this regimen (P ¼ 0.055). Hormone receptor, Her-2/neu expression, previous hormone therapy and age at treatment did not influence therapeutic response (Table 3) . There were 10 patients whose tumors were triple-negative, including the one who had an LABC. Among these, one patient reached pCR, five patients reached PR, three patients reached SD and one patient was PD; the overall RR of patients with triple negative breast cancer was 60%.
TOXICITY
Toxicity was assessed in all 50 patients ( Table 4 ). The most common hematologic toxicity was anemia, and the most common non-hematologic toxicity was alopecia. Anemia was also the most common Grade 3/4 toxicity (4/50, 8%), which was followed by leucopenia (3/50, 6%), anesthesia (3/ 50, 6%) and alopecia (2/50, 4%). There was no febrile neutropenia. Only seven (14%) patients had Grade 1/2 nausea and vomiting, and no Grade 3/4 episodes had been reported. Since many patients had been treated before, 43 (86%) patients had Grade 1 anemia and eight (16%) patients had Grade 1 thrombocytopenia even before wPG treatment. 
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DISCUSSION
Breast cancer is now the most common cancer and the secondary causes of cancer death of women in Taiwan. There are several active chemotherapeutic agents, hormone therapies and target therapies for breast cancers which can be used either as a single agent or a combination, generating better OS and PFS in breast cancer patients much longer than before. Many patients of MBC get opportunities to receive several lines of chemotherapy before the end of their life, so the safety and quality of life are much more important for these patients. Although anthracycline is the standard chemotherapy for breast cancers, consequent toxicities and delayed side effects may limit its usage. Many patients with MBC have already received adjuvant treatments with anthracyclines. Under this situation, taxane-based regimens are usually used as standard therapeutics for MBCs. The gemcitabine combination with taxane, especially paclitaxel, had been reported to have a synergistic effect both in in vitro study and in clinical trials. Different toxicity profiles also make gemcitabine and taxane combination a reasonable choice.
In Taiwan, the gemcitabine and paclitaxel combination has been permitted to be used in anthracycline-failed, locally advanced or MBCs. Most local clinical practice followed the protocols in previous clinical trials, which combined weekly gemcitabine with triweekly paclitaxel. Delfino et al. used gemcitabine (1250 mg/m 2 on days 1 and 8) with triweekly paclitaxel (175 mg/m 2 on day 1) as the first-line therapy for MBC. The RR was 66.7%, CR 22.2%, PR 44.4%, SD 15.6% and PD 17.8%. The median duration of response was 18 months and the median time to tumor progression was 11 months. Grade 3/4 leukopenia, neutropenia and thrombocytopenia developed in 13.3% of the patients, and 15.5% developed Grade 3/4 mucositis (19). Allouache et al. used almost the same dose and schedule for LABC or MBC. Among the 40 enrolled patients, 2 had CR and 12 PR, leading to an overall RR of 35.0% in intent-to-treat population. Among 35 patients who were available for efficacy evaluation, the RR was 40%. Additional 14 patients had SD and 7 had PD. The median duration of response was 12 months, the median TTP was 7.2 months and the median survival was 25.7 months. Common Grade 3/4 toxicities were neutropenia in 17 (42.5%) patients, Grade 3 leukopenia in 19 (47.5%) and Grade 3 alopecia in 30 (75.0%) patients. One (2.5%) patient had Grade 4 thrombocytopenia (10). The study of Sparano et al. showed that weekly paclitaxel was also as effective as triweekly docetaxel but was with less severe myelosuppression. Weekly paclitaxel is also more effective than triweekly paclitaxel and weekly docetaxel in improving disease-free survival and OS in women with breast cancer after adjuvant chemotherapy with doxorubicin and cyclophosphamide (20) . Therefore, it should be more effective and safe to combine weekly paclitaxel and gemcitabine for patients with MBC, especially who have been heavily treated before.
In a randomized Phase II trial of non-small-cell lung cancer (NSCLC) comparing gemcitabine plus weekly paclitaxel vs. triweekly paclitaxel in previously untreated advanced NSCLC, the triweekly paclitaxel regimen was gemcitabine 1000 mg/m 2 on days 1 and 8 and paclitaxel 200 mg/m 2 on day 1 of a 21-day cycle; paclitaxel weekly regimen was gemcitabine 1000 mg/m 2 and paclitaxel 100 mg/m 2 both administered on days 1 and 8 of a 21-day cycle. Compared with triweekly paclitaxel and gemcitabine, weekly paclitaxel and gemcitabine showed equal RR (28.2 vs. 26.8%), longer median survival (10.3 vs. 7.9 months) and a 2-folded lower frequency of Grade 3/4 hematologic events (21) . The wPG combination is safer than the triweekly schedule regimen while they have compatible effects.
Another study used weekly paclitaxel and gemcitabine as a neoadjuvant therapy in patients with Stage II and III breast cancer. The primary endpoint was to evaluate pCR rate and adverse events. Node-positive patients with Stage II and III breast cancer received paclitaxel 80 mg/m 2 followed by gemcitabine 1200 mg/m 2 on days 1 and 8, every 3 weeks for four cycles. Among 44 enrolled patients, 8 patients achieved pCR in primary tumors (18%), 11 in axillary nodes (25%) and 5 in both tumor and axillary nodes (11%). Grade 3/4 toxicities were neutropenia (57%), leukopenia (14%), febrile neutropenia (2%) and headache (2%) (22) . The high efficacy shown in this study might be attributable to the weekly administration schedule of paclitaxel and the sequencedependent synergism of paclitaxel and gemcitabine, but there was still higher incidence of Grade 3/4 neutropenia, and the dosage should be modified.
In our studied treatment, 13 patients received the wPG regimen as the first-line treatment for MBC; 7 patients received it as the second line treatment. The RR in these 20 patients was 80% (1 pCR, 1 clinical CR and 14 PR) and only 1 patient developed PD. In addition, in patients who received this treatment with more than two line-ups of chemotherapies, there were still 12 (42.9%) patients reached PR. Patients who received this regimen earlier can reach significantly better response. The results indicated that the excellent therapeutic effect still could be reached, although the schedule and dosage of paclitaxel and gemcitabine were not as heavy as they were in other clinical trials (23) . The major non-hematologic side effect of weekly paclitaxel is the incidence of neuropathy, which is significantly more frequent in patients treated with triweekly paclitaxel (20) . It is worth to know that only three patients experienced Grade 3/4 peripheral neuropathy in our current study.
Although more than one half of our patients had been treated with either anthracycline or taxane as an adjuvant or salvage therapy, it did not influence therapeutic outcomes compared with no previous anthracycline-or taxane-treated MBC patients. Only patients who had been treated with fluorouracil-contained regimen had significant worse outcomes. The reason could be that there is no cross-resistance between anthracycline and gemcitabine, and the sequential administration of taxane and gemcitabine has synergistic effect, which is better than taxane alone. On the contrary, fluorouracil and gemcitabine are both classified as antimetabolic agents; once tumor progressed during fluorouracil treatment, tumor cells might have the chance to develop resistance to other antimetabolic drugs.
The median PFS of our wPG treatment was 7.4 months, which was not as good as Delfino's trial, but was at least equal to Allouache's study. The reason could be that most of our patients received this treatment after at least two lines of treatment. The median OS of our patients was 19.0 months; although this result is not very impressive, what is noteworthy is that the Grade 3/4 hematologic and nonhematologic toxicities occurred in fewer than 10% of the patients. This excellent toxicity profiles enabled us to administer this treatment safely on days 1, 8 and 15 in a 28-day course and could reach a better dose-dense effect.
In breast cancer, many treatment options at present, quality of life and the side effect from treatment are important issues. Major toxicities of previous paclitaxel and gemcitabine combination regimen were myelosuppression and neuropathy. In comparison with previous regimens, our wPG combination showed better tolerance and equal efficacy. For patients who are heavily pretreated, this regimen can be a good option.
Since the toxicities of this regimen are less severe, in the future, we will try to use this regimen to worse performance status or elderly patients; also the combination effects with target therapy should be tested. We will also analyze the biomarkers of these patients and try to find a predictive marker if possible.
In conclusion, the combination of weekly gemcitabine and paclitaxel in patients with LABC or MBC showed acceptable outcome and excellent toxicity profiles. Efficacy data shown in this case-series study were similar to the result reported in previous studies which combined weekly gemcitabine with triweekly paclitaxel. There are less severe hematologic and non-hematologic toxicities which make wPG combination a good choice for patients of MBC, either at the first-line treatment or at the later line-up.
